Cargando…

New Therapies of Liver Diseases: Hepatic Encephalopathy

Hepatic encephalopathy (HE) is a common complication of advanced liver disease which has profound implications in terms of the patients’ ability to fulfil their family and social roles, to drive and to provide for themselves. Recurrent and persistent HE is still a serious management challenge, trans...

Descripción completa

Detalles Bibliográficos
Autores principales: Mangini, Chiara, Montagnese, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472037/
https://www.ncbi.nlm.nih.gov/pubmed/34575157
http://dx.doi.org/10.3390/jcm10184050
_version_ 1784574625018019840
author Mangini, Chiara
Montagnese, Sara
author_facet Mangini, Chiara
Montagnese, Sara
author_sort Mangini, Chiara
collection PubMed
description Hepatic encephalopathy (HE) is a common complication of advanced liver disease which has profound implications in terms of the patients’ ability to fulfil their family and social roles, to drive and to provide for themselves. Recurrent and persistent HE is still a serious management challenge, translating into a significant burden for patients and their families, health services and society at large. The past few years have been characterized by significantly more attention towards HE and its implications; its definition has been refined and a small number of new drugs/alternative management strategies have become available, while others are underway. In this narrative review we summarize them in a pragmatic and hopefully useful fashion.
format Online
Article
Text
id pubmed-8472037
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84720372021-09-28 New Therapies of Liver Diseases: Hepatic Encephalopathy Mangini, Chiara Montagnese, Sara J Clin Med Review Hepatic encephalopathy (HE) is a common complication of advanced liver disease which has profound implications in terms of the patients’ ability to fulfil their family and social roles, to drive and to provide for themselves. Recurrent and persistent HE is still a serious management challenge, translating into a significant burden for patients and their families, health services and society at large. The past few years have been characterized by significantly more attention towards HE and its implications; its definition has been refined and a small number of new drugs/alternative management strategies have become available, while others are underway. In this narrative review we summarize them in a pragmatic and hopefully useful fashion. MDPI 2021-09-07 /pmc/articles/PMC8472037/ /pubmed/34575157 http://dx.doi.org/10.3390/jcm10184050 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mangini, Chiara
Montagnese, Sara
New Therapies of Liver Diseases: Hepatic Encephalopathy
title New Therapies of Liver Diseases: Hepatic Encephalopathy
title_full New Therapies of Liver Diseases: Hepatic Encephalopathy
title_fullStr New Therapies of Liver Diseases: Hepatic Encephalopathy
title_full_unstemmed New Therapies of Liver Diseases: Hepatic Encephalopathy
title_short New Therapies of Liver Diseases: Hepatic Encephalopathy
title_sort new therapies of liver diseases: hepatic encephalopathy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472037/
https://www.ncbi.nlm.nih.gov/pubmed/34575157
http://dx.doi.org/10.3390/jcm10184050
work_keys_str_mv AT manginichiara newtherapiesofliverdiseaseshepaticencephalopathy
AT montagnesesara newtherapiesofliverdiseaseshepaticencephalopathy